Engineered Extracellular Vesicles for Delivery of an IL‐1 Receptor Antagonist Promote Targeted Repair of Retinal Degeneration
Small · 2023
DOI: 10.1002/smll.202302962 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2023. Verfasst von Yizong Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Eye Center, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, P. R. China. Hauptthemen laut MEDLINE: Retinal Degeneration, Extracellular Vesicles, Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, fundRefName="National Natural Science Foundation of China" funderDoi="10.13039/501100001809">NSFC.
Abstract (Originalsprache)
Retinal degeneration (RD) is an irreversible blinding disease that seriously affects patients’ daily activities and mental health. Targeting hyperactivated microglia and regulating polarization are promising strategies for treating the disease. Mesenchymal stem cell (MSC) transplantation is proven to be an effective treatment due to its immunomodulatory and regenerative properties. However, the low efficiency of cell migration and integration of MSCs remains a major obstacle to clinical use. The goal of this study is to develop a nanodelivery system that targets hyperactivated microglia and inhibits their release of proinflammatory factors, to achieve durable neuroprotection. This approach is to engineer extracellular vesicles (EVs) isolated from MSC, modify them with a cyclic RGD (cRGD) peptide on their surface, and load them with an antagonist of the IL‐1 receptor, anakinra. Comparing with non‐engineered EVs, it is observed that engineered cRGD‐EVs exhibit an increased targeting efficiency against hyperactivated microglia and strongly protected photoreceptors in experimental RD cells and animal models. This study provides a strategy to improve drug delivery to degenerated retinas and offers a promising approach to improve the treatment of RD through targeted modulation of the immune microenvironment via engineered cRGD‐EVs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Eye Center, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, P. R. China.
- Department of Hepatobiliary & Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430062, P. R. China.
- Frontier Science Center of Immunology and Metabolism, Medical Research Institute, Wuhan University, Wuhan, Hubei, 430071, P. R. China.
- Department of Geriatrics, Shenzhen People's Hospital, Shenzhen, Guangdong, 518020, P. R. China.
ORCID-Profile: Yin Shen
Förderung
- Fundamental Research Funds for the Central Universities
- fundRefName="National Natural Science Foundation of China" funderDoi="10.13039/501100001809">NSFC
Zitieren
APA
Liu, Y., Xia, P., Yan, F., Yuan, M., Yuan, H., Du, Y., Yan, J., Song, Q., Zhang, T., Hu, D., & Shen, Y. (2023). Engineered Extracellular Vesicles for Delivery of an IL‐1 Receptor Antagonist Promote Targeted Repair of Retinal Degeneration. Small. https://doi.org/10.1002/smll.202302962
Vancouver
Liu Y, Xia P, Yan F, Yuan M, Yuan H, Du Y, et al. Engineered Extracellular Vesicles for Delivery of an IL‐1 Receptor Antagonist Promote Targeted Repair of Retinal Degeneration. Small. 2023. doi:10.1002/smll.202302962
BibTeX
@article{Liu2023,
author = {Liu, Yizong and Xia, Peng and Yan, Feiyue and Yuan, Man and Yuan, Haitao and Du, Yuxin and Yan, Jiangbo and Song, Qiulin and Zhang, Tianlu and Hu, Danping and Shen, Yin},
title = {Engineered Extracellular Vesicles for Delivery of an IL‐1 Receptor Antagonist Promote Targeted Repair of Retinal Degeneration},
journal = {Small},
year = {2023},
doi = {10.1002/smll.202302962}
}
EUVIMED